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Abstract
Background: A non-negligible proportion of individuals diagnosed with cT1 renal cell
carcinoma (RCC) are upstaged to pT3a at final pathology. Few data on oncological
outcomes for these patients are available to determine whether partial nephrectomy
(PN) might jeopardise cancer control.
Objective: To assess, within an international multi-institutional collaboration, whether
PN might undermine cancer control relative to radical nephrectomy (RN) in RCC patients
with unexpected pT3a disease.
Design, setting, and participants: International multi-institutional collaboration includ-
ing patients with cT1abN0M0–pT3a RCC.
Intervention: PN or RN.
Outcome measurements and statistical analysis: We used Kaplan-Meier analyses,
before and after propensity-score matching, to evaluate differences in metastatic
progression (MP) and cancer-specific mortality (CSM) rates during follow-up. Univari-
able and multivariable Cox regression analyses were used to assess predictors of MP and
CSM.
Results and limitations: Overall, 309 patients with cT1abN0M0 RCC (cT1aN0M0, n = 107,
34.6%; cT1bN0M0, n = 202, 65.4%) had pT3a disease according to final pathology.d w
d in
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MP or CSM was observed between the PN and RN cohorts (both p>0.3). On multivariable
analysis, type of surgery (PN vs RN) was not an independent predictor of either MP
(p = 0.3) or CSM (p = 0.4). Limitations include the retrospective design.
Conclusions: In patients with unexpected pT3a RCC at final pathology, PN does not
appear to jeopardise cancer control with regard to MP and CSM.
Patient summary: Cancer control is similar between patients treated with removal of
the entire kidney and those with only partial removal, even if the final histology
examination demonstrates a tumour that is unexpectedly not confined within the
kidney.
© 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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The majority of patients currently diagnosed with renal cell
carcinoma (RCC) harbour small, organ-confined tumours
[1]. In this setting, international urological guidelines rec-
ommend different management options, ranging from sur-
veillance to nephron-sparing surgery, such as partial
nephrectomy (PN) [2–4]. For small renal masses, PN reduces
the risk of cardiovascular morbidity [5] and is associated
with better functional outcomes [6–10] compared to radical
nephrectomy (RN) without compromising cancer control
[11]. However, a non-negligible proportion of individuals
treated with PN show invasion of perirenal sinus fat tissue
or involvement of the inner renal blood vessels at final
pathology and thus are upstaged to stage pT3a [12–
14]. The clinical impact of such upstaging is debated. In
addition, only a few small studies have formally evaluated
the impact of surgical approach (PN vs RN) on oncological
outcomes among patients with cT1 disease who experi-
enced upstaging to pT3a, and these comprise extremely
limited patient cohorts [12–14].
To bridge this gap, we used the largest multi-institu-
tional cohort of patients with clinical T1abN0M0 RCC trea-
ted with PN or RN for whom final pathology revealed
unexpected pT3a disease to investigate the hypothesis that
PN does not compromise cancer control relative to RN in
this subset of patients.
2. Patients and methods
2.1. Study population
For our retrospective analysis we used a multi-institutional database of
surgically treated RCC patients from ten European tertiary care centres.
Specifically, the study cohort consisted of individuals diagnosed with
RCC and treated with either RN or PN between 1988 and 2015. All
individuals were preoperatively staged as cT1N0M0 and were staged
as pT3a at final pathology. Individuals with bilateral kidney cancer or
with monolateral multifocal tumours were not considered.
2.2. Clinical and pathological evaluation
TNM stages were assigned according to the 2009 American Joint Com-
mittee on Cancer/Union Internationale Contre le Cancer classification
[2]. Cases before the introduction of the most recent classification
scheme were reclassified. Clinical tumour size was based on preoperative
imaging and defined as the greatest tumour diameter in centimetres.
Stage cT1 was defined in accordance with the 2009 TNM classification for
RCC: tumour of 7 cm in the greatest dimension, limited to the kidney,Please cite this article in press as: Capitanio U, et al. Does the U
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omy?. Eur Urol Focus (2017), http://dx.doi.org/10.1016/j.euf.2017.and without radiographic signs of extension to the perinephric tissue or
the major veins [2]. Surgery was performed within 3 mo from clinical
staging. All specimens were evaluated by an experienced uropathologist
at each treating institution. Patients were evaluated at 3 mo after surgery
and subsequently according to individualised follow-up schedules com-
prising at least two annual visits.
2.3. Outcomes
The joint primary outcomes were metastatic progression (MP) and
cancer-specific mortality (CSM). MP was defined as retroperitoneal nodal
recurrence or systemic recurrence (skeletal and/or visceral relapse) at
imaging during follow-up. Patients who died from RCC were defined as
having CSM. CSM was defined by the attending urologist or oncologist
who followed the patient and/or from information on the death
certificate.
2.4. Statistical analyses
Descriptive statistics were used to categorise the baseline characteristics
among patients treated with either PN or RN. Frequencies and propor-
tions were reported for categorical variables. Mean, medians, and inter-
quartile ranges were reported for continuous variables. Mann-Whitney U
tests and x2 tests were applied to assess the statistical significance of
differences in medians and proportions, respectively.
The effect of treatment type (PN vs RN) on MP and CSM was assessed
in the overall cohort. Actuarial survival rates at various time points after
PN and RN were calculated.
To account for possible differences between the two groups that
might be related to differences in the surgical approach, propensity-
score matching was performed. Specifically, propensity scores were
computed using a logistic regression model that evaluated the odds of
receiving PN versus RN according to clinical tumour size, age, and year of
surgery. The nearest-neighbour method, with a calliper width of
0.2 times the standard deviation of the logit and a 1-to-1 matching
ratio, was used. After matching, Kaplan-Meier plots were used to graph-
ically depict the survival rates observed for the matched cohorts. Differ-
ences in the rates of MP and CSM were tested using the log-rank test.
To test the hypothesis that treatment type (PN vs RN) may affect the
risk of MP and CSM after surgery, multivariate Cox regression analyses
were performed in the unmatched cohort after adjusting for all clinical
and pathological covariates.
All statistical tests were two-sided with a level of significance set at
p<0.05. Analyses were performed using SPSS version 20 (IBM Corp.,
Somers, NY, USA) for statistical computing and the R software environ-
ment for graphics (version 3.3.0; www.r-project.org).
3. Results
Overall, among 3863 patients with a clinically defined
diagnosis of T1abN0M0 RCC, 309 (8%) harboured pT3anexpected Presence of Non-organ-confined Disease at Final
0M0 Renal Cell Carcinoma Who Underwent Partial Nephrect-
02.020
E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 17 ) X X X – X X X 3
EUF-299; No. of Pages 6disease at final pathology (cT1aN0M0, n = 107, 34.6%;
cT1bN0M0, n = 202, 65.4%). Patients were treated with
either PN (n = 71, 23%) or RN (n = 238, 77%). Relative to
RN, PN cases were treated more recently (p<0.001, Table 1)
and had smaller masses (median tumour size 3.0 vs 5.5 cm,
p<0.001) and a lower proportion of high Fuhrman grade
(G3–4 29.6 vs 47.1%). An open, laparoscopic, and robotic
approach was used in 72.9%, 2.8%, and 24.3% of PN cases, and
60.7%, 36.5%, and 2.8% of RN cases, respectively. No signifi-
cant differences were observed between the PN and RN
groups with regard to patient age and the presence of
necrosis or sarcomatoid features (Table 1). pT3a was defined
according to the presence of perirenal fat invasion only in
82.1% of PN and 43.6% of RN patients (p<0.001; Table 1).
Only six patients (1.9%) had positive surgical margins at
final pathology (0.8 vs 5.6% for RN vs PN; p = 0.01).
After mean follow-up of 52 mo (55 mo for RN vs 43 mo
for PN), local recurrence was recorded in six RN cases (2.8%)
and two PN cases (2.9%). MP at 1, 2, and 5 yr was observed in
9.1%, 13.3%, and 24.1% of cases, respectively (Fig. 1A). CSM
was 3.5%, 10.7%, and 18.4% at 1, 2, and 5 yr, respectivelyTable 1 – Clinical and pathological characteristics of 309 patients treat
clinical cT1abN0M0 renal cell carcinoma for whom pathology revealed
Variable PN (n = 71, 23%) 
Clinical characteristics
Age (yr) 67 (60–76) 
Year of surgery 2010 (2006–2012) 
Tumor size (cm) 3.0 (2.2–4.4) 
Clinical stage, n (%) 
cT1aN0M0 53 (74.6%) 
cT1bN0M0 18 (25.4%) 
Pathological features
pT3a subclassification (%) 
PFI only 82.1 
SFI only 14.9 
PFI + SFI or PFI/SFI + RVI 3.0 
Surgical margins (%) 5.6 
Fuhrman grade 3–4 (%) 29.6 
Sarcomatoid features (%) 1.5 
Necrosis (%) 26.1 
SFI = sinus fat invasion; PFI = perinephric fat invasion; RVI = renal vein invasion.
Table 2 – Multivariable Cox regression analyses predicting metastatic p
Variable Metastatic progression
HR (95% CI) 
Age 1.0 (1.0–1.1) 
Year of surgery 1.0 (0.9–1.0) 
Tumour size 1.4 (1.0–1.8) 
Fuhrman grade 3–4 1.9 (0.9–3.8) 
Sarcomatoid features 4.3 (1.1–16.3) 
Necrosis 1.1 (0.6–2.3) 
pT3a subclassification 
SFI only vs PFI only 0.9 (0.3–2.3) 
PFI + SFI or PFI/SFI + RVI vs PFI only 1.7 (0.8–3.6) 
Surgical margins 2.3 (0.3–18.4) 
Treatment type
PN vs RN 0.5 (0.1–1.8) 
HR = hazard ratio; CI = confidence interval; SFI = sinus fat invasion; PFI = perin
RN = radical nephrectomy.
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were observed between the PN and RN groups (both p > 0.3;
Figs. 1 B and 2 B).
In multivariable analyses for MP prediction, clinical
tumour size (hazard ratio [HR] 1.4, 95% confidence interval
[CI] 1.0–1.8; p = 0.02) and sarcomatoid features (HR 4.3, 95%
CI 1.1–16.3; p = 0.003) were independent predictors. In
multivariable analyses for CSM prediction, age at surgery
(HR 1.1, 95% CI 1.0–1.1; p = 0.005) and clinical tumour size
(HR 1.4, 95% CI 1.1–1.9; p = 0.03) were independent predic-
tors. Type of surgery (PN vs RN) was not an independent
predictor of either MP (p = 0.3) or CSM (p = 0.4; Table 2).
4. Discussion
International guidelines recommend that RCC patients with
organ-confined tumours should undergo PN whenever
technically feasible, which allows adequate cancer control
and the preservation of functional parenchyma [2–4,15].
The benefits of this approach in terms of the general health
of patients during the follow-up period have been welled with partial nephrectomy (PN) or radical nephrectomy (RN) for
 unexpected pT3a disease.
RN (n = 238, 77%) p value
66 (58–74) 0.6
2006 (2001–2009) <0.001
5.5 (4.2–6.5) <0.001
<0.001
54 (22.7%)
184 (77.3%)
<0.001
43.6
24.1
32.3
0.8 0.01
47.1 0.009
1.8 0.8
37.6 0.1
rogression and cancer-specific mortality.
 Cancer-specific mortality
p value HR (95% CI) p value
0.07 1.1 (1.0–1.1) 0.005
0.6 1.0 (0.9–1.1) 0.5
0.02 1.4 (1.0–1.9) 0.03
0.08 1.8 (0.8–4.2) 0.2
0.03 4.7 (0.8–25.0) 0.07
0.7 1.2 (0.5–2.7) 0.7
0.2 0.7
0.6 (0.2–2.0)
0.9 (0.4–2.3)
0.9 2.7 (0.4–15.1) 0.3
0.3 0.6 (0.1–2.3) 0.4
ephric fat invasion; RVI = renal vein invasion; PN = partial nephrectomy;
nexpected Presence of Non-organ-confined Disease at Final
0M0 Renal Cell Carcinoma Who Underwent Partial Nephrect-
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Fig. 1 – Kaplan-Meier analyses of metastatic progression-free survival
according to surgical treatment (partial vs radical nephrectomy) (A)
before and (B) after propensity-score matching. CE = cumulative events;
NR = number at risk.
Fig. 2 – Kaplan-Meier analyses of cancer-specific mortality-free survival
according to surgical treatment (partial vs radical nephrectomy) (A)
before and (B) after propensity-score matching. CE = cumulative events;
NR = number at risk.
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clinical stage may sometimes underestimate the actual
tumour burden, leading to a pathological upstaging with
potential detrimental effects on a patient’s prognosis in
relation to pathological tumour stage [16]. For approxi-
mately 10–20% of patients with disease staged as cT1N0M0,
final pathology reveals unexpected non-organ-confined
disease (pT3a) owing to the presence of microscopic inva-
sion of the renal vein and/or of the perirenal/sinus fat
[14,17,18]. Computed tomography imaging has sensitivity
of 59–88% and specificity of 71–93% in predicting the pres-
ence of pT3 disease [19]. It has been suggested that cancerPlease cite this article in press as: Capitanio U, et al. Does the U
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omy?. Eur Urol Focus (2017), http://dx.doi.org/10.1016/j.euf.2017.control could be jeopardised relative to RN for this pT3
upstaging in patients who have undergone PN [12–14,20].
Many reports have already assessed potential predictors
of unfavourable characteristics at final pathology in patients
treated with PN [18,20,21]. For instance, Gorin and collea-
gues [13] evaluated the early oncological endpoint of recur-
rence-free survival (RFS) in patients with RCC upstaged
from cT1 to pT3a, but only in the specific setting of robotic
PN. Only 41 patients (4.8%) were upstaged to pT3a. The
24-mo RFS estimates for cT1 and pT3a tumours were 99.2%
and 91.8%, respectively (p = 0.003). Factors associated
with tumour upstaging included high tumour complexitynexpected Presence of Non-organ-confined Disease at Final
0M0 Renal Cell Carcinoma Who Underwent Partial Nephrect-
02.020
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diameter, and hilar location [13]. Ball et al. [18] investigated
predictors associated with adverse pathology, defined as
high pathological grade and/or pT3a disease, among 771 cT1
RCC cases. Male gender, tumour size >4 cm, and high
tumour complexity score were independent predictors of
adverse pathology following PN. These studies and others
focused on upstaging only; however, very few data are
available for comparison of cancer control between PN
and RN in upstaged patients. Nayak et al. [14] assessed
the risk of progression in The Canadian Kidney Cancer
Information System including 1448 clinically defined T1
RCC cases. Overall, 134 patients had disease upstaging to
pT3a (n = 66 PN and n = 68 PN). After median follow-up of
23 mo, the 3-yr RFS was 76% in upstaged patients compared
to 93% in those with no upstaging (p < 0.001). Unfortu-
nately, multivariable analyses comparing the effect of PN
versus RN in the subgroup of patients with upstaging could
not be performed because of the limited sample size
[14]. Jeldres and colleagues [22] performed a multi-institu-
tional matched comparison between PN (n = 30) and RN
(n = 63) cases and found no significant cancer-specific sur-
vival differences after PN for pT3a lesions (HR 2.5; p = 0.9).
Owing to the small cohort size, a subgroup analysis of
cT1N0M0 patients could not be undertaken.
Subgroup analyses for cT1 patients are rarely reported in
the literature, and are exclusively in small cohorts of patients.
Oh et al. [12] carried out a retrospective comparison of PN
versus RN for patients with pT3a M0 RCC who had under-
gone surgery at five institutions in Korea (2000–2010). A
subgroup analysis of 63 cT1a patients upgraded to pT3a
revealed similar RFS rates between PN and RN groups.
To the best of our knowledge, the present study has
evaluated the largest patient cohort available to date for
the current topic. We are unaware of previous reports based
on larger patient samples or of any previous analysis that
relied on propensity-score matching of cohorts. Several
questions might be raised by the current study. First,
although future investigations are needed to draw a defini-
tive conclusion, it might be asked whether the use of frozen
sections during PN is needed in patients with clinically
low-risk, organ-confined, small renal masses when similar
oncological outcomes might be expected regardless of the
surgical procedure. Second, it might be hypothesised that
RN might not necessary in patients with unexpected non–
organ-confined disease at final pathology. Third, it appears
that the surgical procedure should not be a factor when
assessing the most adequate follow-up schedule after sur-
gery. Unfortunately, all those hypotheses can only be for-
mally validated in prospective settings, which are unachie-
vable at present.
Our study is not devoid of limitations. First, the retro-
spective nature must be considered. As a consequence, it is
conceivable that unmeasured variables for patient charac-
teristics might have affected the results. Second, the RN
group comprised individuals with larger and possibly more
complex tumours, for which surgical challenges might have
influenced the decision to perform RN instead of PN. In
addition, PN patients were more represented in the laterPlease cite this article in press as: Capitanio U, et al. Does the U
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omy?. Eur Urol Focus (2017), http://dx.doi.org/10.1016/j.euf.2017.years of the study. However, year of surgery was included in
our multivariable analyses to adjust for potential biases
related to different lengths of follow-up. Third, the lack of
central review for imaging and pathology specimen evalu-
ation must also be considered. Specifically, the ability to
correctly perform an adequate clinical staging depends on
the imaging technique (computed tomography vs magnetic
resonance imaging), the experience of the radiologist, and
the protocols used at each institution.
5. Conclusions
Using a large multi-institutional cohort of cT1N0M0 RCC
patients, we investigated whether PN might undermine
cancer control when unanticipated pT3a disease is found
at final pathology. In this specific scenario, despite the
presence of unexpected non–organ-confined disease, PN
does not seem to jeopardise cancer control.
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